Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019-Reference-Cited by-同舟云学术

Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019

Published:2019-09 Issue:3 Volume:76 Page:368-380
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Grimm Marc-Oliver,Bex Axel,De Santis Maria,Ljungberg Börje,Catto James W.F.,Rouprêt Morgan,Hussain Syed A.,Bellmunt Joaquim,Powles Tom,Wirth Manfred,Van Poppel Hendrik

Publisher

Elsevier BV

Subject

Urology

Reference74 articles.

1. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition;Buchbinder;Am J Clin Oncol,2016

2. Role of checkpoint inhibition in localized bladder cancer;Hahn;Eur Urol Oncol,2018

3. EAU guidelines on renal cell carcinoma;Ljunberg,2019

4. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. In press. http://dx.doi.drg/10.1038/s41571-019-0218-0.

5. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer;Annals of Surgical Oncology;2024-07-12

2. Applications of Biosensors in Bladder Cancer;Critical Reviews in Analytical Chemistry;2024-07-08

3. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study;Biomolecules and Biomedicine;2024-06-25

4. Editorial: Urological cancer awareness month – 2022;Frontiers in Urology;2024-05-20

5. The integrate profiling of single-cell and spatial transcriptome RNA-seq reveals tumor heterogeneity, therapeutic targets, and prognostic subtypes in ccRCC;Cancer Gene Therapy;2024-03-13